课题基金 / 基金详情

BASE CONTRACT: YEAR 1 - PRECLINICAL MEDICATIONS SCREENING IN ALCOHOL PREFERRING RATS. BASE PERIOD (FY-19). PERIOD OF PERFORMANCE: 09/29/19 - 09/28/20.

BASE CONTRACT: YEAR 1 - PRECLINICAL MEDICATIONS SCREENING IN ALCOHOL PREFERRING RATS. BASE PERIOD (FY-19). PERIOD OF PERFORMANCE: 09/29/19 - 09/28/20.
基础合同:第一年 - 在酒精偏好大鼠中进行临床前药物筛选。
批准号:
10037799
负责人:
RICHARD L. BELL, PH.D.
金额:
$38.22万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-29 至 2020-09-28

项目摘要

项目成果

RICHARD L. BELL, PH.D.的其他基金

相似基金

相关文献

中文摘要
翻译
本合同旨在对P和HAD1大鼠自愿饮酒的参比化合物和感兴趣化合物进行盲法药效试验,并对试验结果进行分析。该合同有一项符合《贝赫-多尔法案》的知识产权条款,同时提供了对专有化合物供应商有吸引力的保护。这有助于我们测试最终可能被商业化开发的药物。临床前疗效测试旨在为进一步开发的决策提供信息。
英文摘要
This contract is for the blind efficacy testing of reference compounds and compounds of interest on voluntary alcohol drinking by alcohol preferring P and HAD1 rats and provide analysis of said testing. The contract has an intellectual property clause that is Bayh–Dole Act compliant, while offering protection that is attractive to proprietary compound suppliers. This facilitates our ability to test drugs that may eventually be developed commercially. The preclinical efficacy test are designed to inform decisions about further development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BASE CONTRACT: YEAR 1 - PRECLINICAL MEDICATIONS SCREENING IN ALCOHOL PREFERRING RATS. BASE PERIOD (FY-19). PERIOD OF PERFORMANCE: 09/29/19 - 09/28/20.
  • 批准号:
    10227891
  • 项目类别:
  • 资助金额:
    $38.29万
  • 财政年份:
    2019
  • 负责人:
    RICHARD L. BELL, PH.D.
  • 依托单位:
PRECLINICAL MEDICATIONS SCREENING
  • 批准号:
    10475556
  • 项目类别:
  • 资助金额:
    $39.03万
  • 财政年份:
    2019
  • 负责人:
    RICHARD L. BELL, PH.D.
  • 依托单位:
PRECLINICAL MEDICATIONS SCREENING
  • 批准号:
    10683912
  • 项目类别:
  • 资助金额:
    $39.77万
  • 财政年份:
    2019
  • 负责人:
    RICHARD L. BELL, PH.D.
  • 依托单位:
EO14042 - PRECLINICAL MEDICATIONS SCREENING IN ALCOHOL PREFERRING RATS
  • 批准号:
    10954022
  • 项目类别:
  • 资助金额:
    $40.5万
  • 财政年份:
    2019
  • 负责人:
    RICHARD L. BELL, PH.D.
  • 依托单位:
海外基金